Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Everence Capital Management Inc.
Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...
Analysts Set Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target at $494.04
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, ...
Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Levi & Korsinsky Reminds Vertex Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities Laws - VRTX
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Zacks.com on MSN3d
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...
Shareholders that lost money on Vertex Pharmaceuticals Incorporated(VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTX
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals Incorporated (VRTX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
Vertex Pharmaceuticals' suzetrigine is an investigational pain treatment. It will seek label expansions thereafter, including ...
Zacks Research Has Positive Estimate for VRTX Q3 Earnings
Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
Once high-flying, bluebird bio now faces an uncertain future
The future of the trailblazing gene therapy company bluebird bio Inc. — which was once worth nearly as much as the airline JetBlue — is now uncertain as it looks to extend its cash runway, which ...
Business Insider9d
Shareholder Rights Advocates at Levi & Korsinsky Investigate Vertex Pharmaceuticals Incorporated (VRTX) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") ...